Johnson & Johnson discontinues three neuroscience programs—including the sleep-focused seltorexant—realigning its R&D priorities and signaling a strategic course …
Johnson & Johnson discontinues three neuroscience programs—including the sleep-focused seltorexant—realigning its R&D priorities and signaling a strategic course …
At the 2025 ASCO Gastrointestinal Cancers Symposium, ALX Oncology presents promising Phase II data showing that evorpacept, a …
The European Medicines Agency approves GSK’s PD-1 inhibitor, Jemperli, in combination with chemotherapy as a first-line therapy for …
The 43rd annual J.P. Morgan Healthcare Conference begins in San Francisco under tighter security and market uncertainty, but …
A three-year collaboration between Vertex and Orna Therapeutics brings cutting-edge lipid nanoparticle delivery into the spotlight, aiming to …
In a late-2024 milestone, the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for Mesoblast’s stromal cell therapy injects …
The Phase III ENGOT-OV44/First trial delivers a milestone in ovarian cancer research, suggesting immunotherapy could redefine standard of …
With its first-in-class mechanism and monthly dosing, Depemokimab sets a new benchmark in biologic treatment for high-burden asthma …
Semaglutide’s latest trial reveals significant reduction in heart failure hospitalizations, expanding its role in cardiometabolic care.
GSK’s long-acting biologic reduces exacerbations and improves lung function in eosinophilic asthma, offering a potential once-yearly treatment option.
Already a subscriber? Log in